Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and therapy-resistant cancer with an overall 5-year survival rate of almost 12%, making it among the most lethal of all major cancers.1 PDAC has a distinct genomic profile, with somatic KRAS protooncogene mutations in ~90% of cases.2,3 Current literature has not reached a consensus on disease prognosis based on KRAS mutation subtype.2-5https://jdc.jefferson.edu/aoa_research_symposium_posters/1005/thumbnail.jp
